Previous 10 | Next 10 |
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies London Healthcare Conference. The presentation will be made available for on-demand listening be...
Announced Clinical Collaboration with Amgen to Evaluate VS-6766 with LUMAKRAS™ in Non-Small Cell Lung Cancer in Upcoming Clinical Trial Updated Data from Investigator-Sponsored Phase 1/2 FRAME Study of VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer Presented ...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021. Ms. Robertson, who is the Chief Financial Officer...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Last week we talked about biotech penny stocks with upcoming catalysts. That article received a lot of attention and for obvious reasons. As I explained, few industries will host companies that will tell you when they’ve got news coming. Biotech is one of these industries, and it...
Verastem Oncology has had a relatively quiet year for most of 2021 but a pair of announcements has provided a burst of excitement that could revitalize investor sentiment. The company’s RAF/MEK dual inhibitor, VS-6766, continues to show encouraging results in LGSOC and NSCLC. ...
Do You Agree With Analysts On These Penny Stocks? With the stock market sell-off this week, investors are jittery. But this hasn’t put a pause on day traders searching for penny stocks to buy. In fact, these last few days of selling have brought waves of retail buying. The name o...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology experti...
Verastem (NASDAQ: VSTM) , a small-cap cancer specialist, saw its shares briefly spike by as much as 29% Monday morning. The drugmaker's stock started today's trading session off on a strong note in response to a clinical collaboration agreement with biotech heavyweight Amgen (...
News, Short Squeeze, Breakout and More Instantly...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...